Key Takeaways
Dr. Reddy’s Laboratories (NYSE: RDY) shares fell 5.2% after the company reported fiscal fourth-quarter adjusted earnings of 6 cents per share, missing the Zacks Consensus Estimate of 9 cents. The company’s earnings release attributed the sharp miss to slumping sales in its North America generics business and price erosion.
The results fell short of market expectations across the board, driving the negative investor sentiment. For the quarter ended March 31, 2026, the Indian pharmaceutical company's performance was significantly impacted by competitive pressures and a one-time adjustment.
The stock's decline reflects investor disappointment with a 51% year-over-year drop in the North America segment, driven by lower sales of the cancer drug lenalidomide and a one-time Shelf Stock Adjustment of INR 4.5 billion related to the product. The company's gross margin contracted by 1,074 basis points to 44.8%, further pressuring profitability.
The core of the company's weak performance came from its Global Generics segment, which saw revenues decline 13% year-over-year to INR 65.8 billion. While Dr. Reddy's launched seven new products in North America during the quarter, it was not enough to offset the decline in lenalidomide sales and broader price erosion. For the full fiscal year 2026, revenues grew a modest 3% to $3.58 billion, while adjusted earnings per share fell to 59 cents from 79 cents in fiscal 2025.
Selling, general and administrative expenses rose 15% to $296 million, driven by investments in its branded franchises and a potential VAT liability in a subsidiary. In contrast, research and development expenses were down 25% to $58 million.
Despite the challenging quarter, Dr. Reddy's announced several strategic moves aimed at future growth. The company's biologics license application for DRL_AB, a proposed biosimilar to Bristol Myers' (BMY) Orencia, was accepted for review by the FDA. If approved, it would be the first biosimilar of Orencia in the United States.
In India, the company entered the growing GLP-1 market with the launch of Obeda, the country's first regulatory-approved generic version of Novo Nordisk's (NVO) Ozempic for type II diabetes. It also acquired two hormone replacement therapy brands from Mercury Pharma Group, strengthening its women's health portfolio in the country.
The weak quarter highlights significant pricing pressure in the U.S. generics market, a headwind for peers like Amarin Corporation (AMRN) as well. Investors will now watch to see if the launch of new products, like the semaglutide generic Obeda, and the advancement of its biosimilar pipeline can offset these declines in fiscal 2027.
This article is for informational purposes only and does not constitute investment advice.
